Eesti - eesti - Ravimiamet

berlin-chemie ag - ranitidiin - õhukese polümeerikattega tablett - 300mg 50tk; 300mg 20tk

Eesti - eesti - Ravimiamet

berlin-chemie ag - ranitidiin - õhukese polümeerikattega tablett - 150mg 50tk; 150mg 20tk

Eesti - eesti - Ravimiamet

berlin-chemie ag - lipaas+amülaas+proteaas - gastroresistentne tablett - 10000ühik+7500ühik+375ühik 50tk; 10000ühik+7500ühik+375ühik 100tk; 10000ühik+7500ühik+375ühik 20tk

Eesti - eesti - Ravimiamet

berlin-chemie ag - metformiin - õhukese polümeerikattega tablett - 850mg 60tk; 850mg 120tk; 850mg 30tk

Eesti - eesti - Ravimiamet

berlin-chemie ag - ambroksool - suukaudne lahus - 3mg 1ml 60ml 1tk; 3mg 1ml 100ml 1tk

Eesti - eesti - Ravimiamet

a. menarini manufacturing logistics and services s.r.l. - tramadool - kõvakapsel - 50mg 2tk

Eesti - eesti - Ravimiamet

a. menarini manufacturing logistics and services s.r.l. - tramadool+deksketoprofeen - õhukese polümeerikattega tablett - 75mg+25mg 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

stemline therapeutics b.v. - tagraxofusp - lymphoma - antineoplastilised ained - elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (bpdcn).

Euroopa Liit - eesti - EMA (European Medicines Agency)

stemline therapeutics b.v. - selinexor - mitu müeloomit - antineoplastilised ained - nexpovio is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Euroopa Liit - eesti - EMA (European Medicines Agency)

stemline therapeutics b.v. - elacestrant - rinnanäärmed - endokriinset ravi - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.